STING1 and viral infectious disease: On this basis, both in vivo and in vitro studies highlighted that early treatments with STING agonists, e.g., diABZI, are promising therapeutic options to govern viral infection by limiting viral replication and inflammatory response in an IFN-dependent manner [77].